Contents

Issue 128 • March 2023

In association with

‘Right shoring’ API production in Europe

Amidst rising inflation and ongoing drug shortages, is the EU is at risk of getting ‘right-shoring’ wrong?

IN DEPTH

Inside the hunt for an Alzheimer’s disease vaccine

Comment

Price is key for market adoption of Amgen’s Amjevita

Briefing

Industry news

Pharma industry briefing

Comment

4D Molecular’s Fabry gene therapy program on FDA clinical hold

Price is key for market adoption of Amgen’s Amjevita

Wegovy: the latest weight loss fad

PROTAC development gains momentum, but clinical performance is poor

FDA head Califf calls on tighter accelerated approvals and lower drug prices

In Depth

‘Right shoring’ API production in Europe

Provention’s Tzield can delay type 1 diabetes. But will it reach all patients?

DCTs in 2023: New year’s resolutions for decentralised clinical trials

Inside the hunt for an Alzheimer’s disease vaccine

Are we entering the era of biologics for COPD?

CMO Moves: Regulatory catalysts for drug manufacturing-February

In Data

The pharma industry found it easier to fill AI vacancies in Q3 2022

Internet of things hiring levels in the pharma dropped in October 2022

Artificial intelligence hiring levels in pharma dropped in October 2022

02/23/2023 19:50:48
  • Home | ‘Right shoring’ API production in Europe
  • In this issue
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Briefing
  • Industry news
  • The pharma industry briefing
  • HOF Sonderanlagenbau
  • BEA Technologies
  • Comment
  • 4D Molecular’s Fabry gene therapy program on FDA clinical hold
  • Price is key for wider market adoption of Amgen’s Amjevita
  • Wegovy: the latest weight loss fad
  • PROTAC development gains momentum, but clinical performance is poor
  • FDA head Califf on tighter accelerated approvals and lower drug prices
  • In Depth
  • ‘Right shoring’ API production in Europe
  • Provention’s Tzield can delay type 1 diabetes. But will it reach all patients?
  • DCTs in 2023: New year’s resolutions for decentralised clinical trials
  • Inside the hunt for an Alzheimer’s disease vaccine
  • Are we entering the era of biologics for COPD?
  • CMO Moves: Regulatory catalysts for drug manufacturing – February
  • Events
  • Next issue